Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is Acuta Capital Partners LLC’s 10th Largest Position

Acuta Capital Partners LLC reduced its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 9.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,118,992 shares of the company’s stock after selling 211,945 shares during the period. Taysha Gene Therapies accounts for about 3.4% of Acuta Capital Partners LLC’s holdings, making the stock its 10th biggest holding. Acuta Capital Partners LLC owned approximately 1.03% of Taysha Gene Therapies worth $4,259,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Creative Planning acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. increased its position in shares of Taysha Gene Therapies by 79.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after acquiring an additional 17,446 shares during the last quarter. Privium Fund Management B.V. raised its stake in shares of Taysha Gene Therapies by 21.8% in the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock valued at $241,000 after acquiring an additional 21,500 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $48,000. Finally, Quantum Private Wealth LLC increased its holdings in Taysha Gene Therapies by 4.6% in the 2nd quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock valued at $1,636,000 after purchasing an additional 32,000 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on TSHA shares. Canaccord Genuity Group raised their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Chardan Capital restated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Trading Up 2.4 %

Shares of NASDAQ:TSHA opened at $3.00 on Thursday. Taysha Gene Therapies, Inc. has a 52 week low of $1.19 and a 52 week high of $4.32. The company’s 50 day moving average is $2.02 and its two-hundred day moving average is $2.38. The company has a market cap of $614.83 million, a PE ratio of 4.76 and a beta of 0.44. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.